1.A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor.
Joonhong SOHN ; Ju Byung CHAE ; Sun Young LEE ; Soo Youl KIM ; June Gone KIM
Korean Journal of Ophthalmology 2010;24(1):29-34
PURPOSE: Our goal was to investigate the effects of inhibition of transglutaminase 2 (TGase 2) on endotoxin-induced uveitis (EIU) METHODS: EIU was induced in female Lewis rats by single footpad injections of 200 microgram of lipopolysaccharide (LPS). TGase 2 inhibitors were administered intraperitoneally 30 minutes before and at the time of LPS administration. Rats were sacrificed 24 hours after injection, and the effects of the TGase 2 inhibitors were evaluated by the number of intraocular inflammatory cells present on histologic sections and by measuring the TGase 2 activity and TGase products in the aqueous humor (AqH). TGase 2 substrates were also assayed in AqH from uveitis patients. RESULTS: Clinical indications of EIU, the number of cells present on histologic sections, and TGase 2 activity in AqH increased in a time-dependent manner, peaking 24 hours after LPS injection. Inflammation in EIU was significantly reversed by treatment with TGase inhibitors. A 23-kDa cross-linked TGase substrate was identified in the AqH from EIU rats and uveitis patients. MALDI-TOF analysis showed that this substrate in uveitis patients was human Ig kappa chain C region. CONCLUSIONS: TGase 2 activity and its catalytic product were increased in the AqH of EIU rats. TGase 2 inhibition attenuated the degree of inflammation in EIU. Safe and stable TGase inhibitors may have great potential for the treatment of inflammatory uveitis.
Animals
;
Disease Progression
;
Enzyme Inhibitors/*therapeutic use
;
Female
;
GTP-Binding Proteins/*antagonists & inhibitors/*metabolism
;
Lipopolysaccharides
;
Rats
;
Rats, Inbred Lew
;
Transglutaminases/*antagonists & inhibitors/*metabolism
;
Uveitis/chemically induced/*enzymology/pathology
2.Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine.
Ju Hong JEON ; Hye Jin LEE ; Gi Yong JANG ; Chai Wan KIM ; Dong Myung SHIN ; Sung Yup CHO ; Eui Ju YEO ; Sang Chul PARK ; In Gyu KIM
Experimental & Molecular Medicine 2004;36(6):576-581
The treatment of cystamine, a transglutaminase (TGase) inhibitor, has beneficial effects in several diseases including CAG-expansion disorders and cataract. We compared the inhibition characteristics of cystamine with those of cysteamine, a reduced form of cystamine expected to be present inside cells. Cystamine is a more potent inhibitor for TGase than cysteamine with different kinetics pattern in a non- reducing condition. By contrast, under reducing conditions, the inhibitory effect of cystamine was comparable with that of cysteamine. However, cystamine inhibited intracellular TGase activity more strongly than cysteamine despite of cytoplasmic reducing environment, suggesting that cystamine itself inhibits in situ TGase activity by forming mixed disulfides.
Cell Line, Tumor
;
Comparative Study
;
Cystamine/*pharmacology
;
Cysteamine/*pharmacology
;
Enzyme Inhibitors/*pharmacology
;
Humans
;
Research Support, Non-U.S. Gov't
;
Transglutaminases/*antagonists & inhibitors
3.Effects of Transglutaminase 2 Inhibition on Ventilator-Induced Lung Injury.
In Bum SUH ; Dae Wui YOON ; Won Oak OH ; Eun Joo LEE ; Kyung Hoon MIN ; Gyu Young HUR ; Seung Heon LEE ; Sung Yong LEE ; Sang Yeub LEE ; Chol SHIN ; Jae Jeong SHIM ; Kwang Ho IN ; Kyung Ho KANG ; Je Hyeong KIM
Journal of Korean Medical Science 2014;29(4):556-563
This study was performed to examine the role of transglutaminase 2 (TG2) in ventilator-induced lung injury (VILI). C57BL/6 mice were divided into six experimental groups: 1) control group; 2) lipopolysaccharide (LPS) group; 3) lung protective ventilation (LPV) group; 4) VILI group; 5) VILI with cystamine, a TG2 inhibitor, pretreatment (Cyst+VILI) group; and 6) LPV with cystamine pretreatment (Cyst+LPV) group. Acute lung injury (ALI) score, TG2 activity and gene expression, inflammatory cytokines, and nuclear factor-kappaB (NF-kappaB) activity were measured. TG2 activity and gene expression were significantly increased in the VILI group (P < 0.05). Cystamine pretreatment significantly decreased TG2 activity and gene expression in the Cyst+VILI group (P < 0.05). Inflammatory cytokines were higher in the VILI group than in the LPS and LPV groups (P < 0.05), and significantly lower in the Cyst+VILI group than the VILI group (P < 0.05). NF-kappaB activity was increased in the VILI group compared with the LPS and LPV groups (P < 0.05), and significantly decreased in the Cyst+VILI group compared to the VILI group (P = 0.029). The ALI score of the Cyst+VILI group was lower than the VILI group, but the difference was not statistically significant (P = 0.105). These results suggest potential roles of TG2 in the pathogenesis of VILI.
Acute Lung Injury/pathology
;
Animals
;
Cystamine/therapeutic use
;
Cytokines/analysis
;
Enzyme Inhibitors/therapeutic use
;
Enzyme-Linked Immunosorbent Assay
;
GTP-Binding Proteins/*antagonists & inhibitors/genetics/metabolism
;
Gene Expression
;
Lipopolysaccharides/toxicity
;
Male
;
Mice
;
Mice, Inbred C57BL
;
NF-kappa B/metabolism
;
Respiration, Artificial
;
Transglutaminases/*antagonists & inhibitors/genetics/metabolism
;
Ventilator-Induced Lung Injury/*enzymology/pathology/prevention & control
4.Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Jae Heon JEONG ; Byoung Chul CHO ; Hyo Sup SHIM ; Hye Ryun KIM ; Sun Min LIM ; Se Kyu KIM ; Kyung Young CHUNG ; S M Bakhtiar Ul ISLAM ; Jae Jin SONG ; Soo Youl KIM ; Joo Hang KIM
Journal of Korean Medical Science 2013;28(7):1005-1014
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-kappaB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-kappaB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-kappaB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-kappaB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI.
Adenocarcinoma/*drug therapy/mortality/surgery
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/surgery
;
Disease-Free Survival
;
Female
;
GTP-Binding Proteins/*biosynthesis
;
Humans
;
Lung Neoplasms/*drug therapy/mortality/surgery
;
Male
;
Middle Aged
;
NF-kappa B/biosynthesis
;
Protein Kinase Inhibitors/therapeutic use
;
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/genetics
;
Transglutaminases/*biosynthesis
;
Treatment Outcome